A detailed history of Jane Street Group, LLC transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 79,537 shares of IDYA stock, worth $2.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
79,537
Previous 129,013 38.35%
Holding current value
$2.13 Million
Previous $4.53 Million 44.38%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$30.37 - $43.05 $1.5 Million - $2.13 Million
-49,476 Reduced 38.35%
79,537 $2.52 Million
Q2 2024

Aug 14, 2024

BUY
$34.37 - $43.46 $3.41 Million - $4.31 Million
99,235 Added 333.25%
129,013 $4.53 Million
Q1 2024

May 15, 2024

SELL
$34.2 - $47.13 $385,057 - $530,636
-11,259 Reduced 27.44%
29,778 $1.31 Million
Q4 2023

Feb 14, 2024

BUY
$24.59 - $35.83 $568,496 - $828,353
23,119 Added 129.03%
41,037 $1.46 Million
Q3 2023

Nov 14, 2023

SELL
$21.07 - $29.77 $911,635 - $1.29 Million
-43,267 Reduced 70.72%
17,918 $483,000
Q2 2023

Aug 14, 2023

SELL
$13.33 - $25.53 $26,620 - $50,983
-1,997 Reduced 3.16%
61,185 $1.44 Million
Q1 2023

May 15, 2023

BUY
$13.49 - $18.72 $667,701 - $926,565
49,496 Added 361.65%
63,182 $867,000
Q4 2022

Feb 14, 2023

BUY
$14.47 - $18.17 $198,036 - $248,674
13,686 New
13,686 $248,000
Q1 2022

May 17, 2022

SELL
$11.18 - $24.02 $171,735 - $368,971
-15,361 Closed
0 $0
Q4 2021

Feb 15, 2022

BUY
$20.95 - $26.88 $321,812 - $412,903
15,361 New
15,361 $363,000
Q3 2020

Nov 17, 2020

SELL
$11.22 - $14.46 $140,855 - $181,530
-12,554 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$3.59 - $18.57 $45,068 - $233,127
12,554 New
12,554 $179,000

Others Institutions Holding IDYA

About IDEAYA Biosciences, Inc.


  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.29B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.